HomeCompareBXSL vs SYK

BXSL vs SYK: Dividend Comparison 2026

BXSL yields 12.95% · SYK yields 1.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXSL wins by $693438.02M in total portfolio value
10 years
BXSL
BXSL
● Live price
12.95%
Share price
$23.79
Annual div
$3.08
5Y div CAGR
94.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$693438.07M
Annual income
$680,033,607,476.38
Full BXSL calculator →
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →

Portfolio growth — BXSL vs SYK

📍 BXSL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXSLSYK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXSL + SYK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXSL pays
SYK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXSL
Annual income on $10K today (after 15% tax)
$1,100.46/yr
After 10yr DRIP, annual income (after tax)
$578,028,566,354.92/yr
SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
At 15% tax rate, BXSL beats the other by $578,028,559,314.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXSL + SYK for your $10,000?

BXSL: 50%SYK: 50%
100% SYK50/50100% BXSL
Portfolio after 10yr
$346719.05M
Annual income
$340,016,807,879.68/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

BXSL
Analyst Ratings
9
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$26.00
+9.3% upside vs current
Range: $24.00 — $28.00
Altman Z
0.6
Piotroski
3/9
SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXSL buys
0
SYK buys
6
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$SYK▼ Sell$15,001 - $50,0002026-01-23
Thomas H. Kean🏢 House$SYK▼ Sell$15,001 - $50,0002025-11-20
Ro Khanna🏢 House$SYK▼ Sell$1,001 - $15,0002025-10-07
Thomas H. Kean🏢 House$SYK▼ Sell$15,001 - $50,0002025-09-12
Thomas H. Kean🏢 House$SYK▼ Sell$1,001 - $15,0002025-08-25
Thomas H. Kean🏢 House$SYK▼ Sell$15,001 - $50,0002025-07-31
Thomas H. Kean🏢 House$SYK▼ Sell$15,001 - $50,0002025-06-26
Rob Bresnahan🏢 House$SYK▼ Sell$1,001 - $15,0002025-04-08
Jared Moskowitz🏢 House$SYK▲ Buy$1,001 - $15,0002025-04-07
Jefferson Shreve🏢 House$SYK▼ Sell$50,001 - $100,0002025-03-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXSLSYK
Forward yield12.95%1.04%
Annual dividend / share$3.08$3.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR94.4%46.2%
Portfolio after 10y$693438.07M$43.3K
Annual income after 10y$680,033,607,476.38$8,282.98
Total dividends collected$692530.98M$21.0K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusBuyBuy
Analyst price target$26.00$428.67

Year-by-year: BXSL vs SYK ($10,000, DRIP)

YearBXSL PortfolioBXSL Income/yrSYK PortfolioSYK Income/yrGap
1← crossover$13,217$2,516.82$10,852$152.43+$2.4KBXSL
2$20,186$6,043.55$11,838$226.03+$8.3KBXSL
3$38,368$16,769.42$13,004$336.89+$25.4KBXSL
4$98,964$57,910.68$14,420$505.63+$84.5KBXSL
5$377,274$271,382.26$16,195$766.09+$361.1KBXSL
6$2,283,312$1,879,628.45$18,504$1,175.64+$2.26MBXSL
7$23,110,868$20,667,724.06$21,635$1,835.40+$23.09MBXSL
8$404,792,131$380,063,502.87$26,082$2,932.10+$404.77MBXSL
9$12,527,531,257$12,094,403,676.51$32,737$4,829.68+$12527.50MBXSL
10$693,438,065,921$680,033,607,476.38$43,312$8,282.98+$693438.02MBXSL

BXSL vs SYK: Complete Analysis 2026

BXSLBDC

Blackstone Secured Lending Fund is business development company and a Delaware statutory trust formed on March 26, 2018, and structured as an externally managed, non-diversified closed-end investment Fund. On October 26, 2018, the fund elected to be regulated as a business development company (BDC) under the Investment Company Act of 1940, as amended (the 1940 Act). In addition, the Fund elected to be treated for U.S. federal income tax purposes, as a regulated investment company (RIC), as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the Code). The fund also intends to continue to comply with the requirements prescribed by the Code in order to maintain tax treatment as a RIC. The fund's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The Fund seeks to achieve its investment objective primarily through originated loans, equity and other securities, including syndicated loans, of private U.S. companies, specifically small and middle market companies, typically in the form of first lien senior secured and unitranche loans (including first out/last out loans), and to a lesser extent, second lien, third lien, unsecured and subordinated loans and other debt and equity securities.

Full BXSL Calculator →

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →
📬

Get this BXSL vs SYK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXSL vs SCHDBXSL vs JEPIBXSL vs OBXSL vs KOBXSL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.